Tier 2 — strong

Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials

Hua Qu, Ming Guo, Hua Chai, Wen-ting Wang, Zhu-ye Gao, Da-zhuo Shi
Journal of the American Heart Association 2018

Bibliography

PubMed
PMID 30371340
PubMed Central
PMC6404871
DOI
10.1161/JAHA.118.009835
Funding
Supported by the National Natural Science Foundation of China (81030063 and 81303150), National Science and Technology Support Program (2013BAI02B01), and Major National Research and Development Program (2018ZX09201009-002-006).
Competing interests
The authors declared no conflicts of interest.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelUpdated systematic review and meta-analysis of randomized controlled trials evaluating CoQ10 supplementation for statin-associated muscle symptoms and creatine kinase.
Sample12 randomized controlled trials. Nine contributed statin-associated muscle-symptom outcomes and 10 contributed plasma CK; trial sample sizes ranged approximately 37–76 participants.
InterventionCoQ10 versus placebo/control in statin-treated adults; included trials used approximately 100–600 mg/day for 30 days to 3 months.
Duration30 days to 3 months across included trials.
EndpointsMuscle pain; Muscle weakness; Muscle cramps; Muscle tiredness; Creatine kinase; Dose meta-regression; Treatment-duration meta-regression; Publication year meta-regression; Heterogeneity

What the study showed, in plain terms

This 2018 updated meta-analysis reached a different conclusion from the 2015 Banach review. Across 12 randomized trials, pooled symptom scores favored CoQ10 for muscle pain, weakness, cramps and tiredness, while creatine kinase did not improve.

Under the fixed-effect model, pain improved by WMD -1.60 (95% CI -1.75 to -1.44), weakness by -2.28 (95% CI -2.79 to -1.77), cramps by -1.78 (95% CI -2.31 to -1.24), and tiredness by -1.75 (95% CI -2.31 to -1.19). Random-effects analysis still favored CoQ10 for pain (-1.46, 95% CI -2.16 to -0.76) and weakness (-2.54, 95% CI -4.07 to -1.01).

However, pain heterogeneity was extremely high (I²=89.6%), and neither dose, duration nor publication year explained it. CK did not significantly change. This positive synthesis therefore should be presented alongside the negative 2015 and 2020 meta-analyses and the negative confirmed-myalgia Taylor trial rather than as settled proof of efficacy.

Key findings

Fixed-effect symptom results: pain WMD -1.60 (95% CI -1.75 to -1.44; p<0.001); weakness -2.28 (95% CI -2.79 to -1.77; p=0.006); cramps -1.78 (95% CI -2.31 to -1.24; p<0.001); tiredness -1.75 (95% CI -2.31 to -1.19; p<0.001).

Random-effects robustness analysis: pain WMD -1.46 (95% CI -2.16 to -0.76; p<0.001); weakness -2.54 (95% CI -4.07 to -1.01; p=0.006).

Pain heterogeneity: I²=89.6%, p<0.001—very high between-study inconsistency.

Meta-regression did not explain pain heterogeneity by CoQ10 dose, treatment duration or publication year; reported p values were 0.79, 0.98 and 0.31, respectively.

Creatine kinase: no statistically significant pooled reduction, indicating that symptom-score improvement was not accompanied by a consistent biochemical muscle-injury signal.

Doses ranged roughly 100–600 mg/day and trial duration 30 days–3 months, contributing to clinical heterogeneity.

What this study can and cannot tell us

Very high heterogeneity for muscle pain (I²=89.6%) materially weakens confidence in the pooled symptom magnitude.

Trials differed in symptom definitions, pain scales, confirmation of statin causality, statin regimen, CoQ10 dose/formulation and duration.

Most individual RCTs were small, and subjective symptom outcomes are highly vulnerable to nocebo/placebo effects.

The positive pooled result conflicts with other meta-analyses and with a rigorously confirmed-statин-myalgia RCT. The disagreement should be shown transparently rather than selecting only the favorable synthesis.

No consistent CK benefit was detected, so the meta-analysis does not show reversal of objective muscle injury.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology